• LINC01278 Suppresses Uveal Melanoma via mTOR Pathway Autopha

  2026-04-21

  This study identifies LINC01278 as a tumor suppressor in uveal melanoma, acting through mTOR pathway inhibition to induce autophagy. The findings clarify a mechanistic LINC01278–mTOR–autophagy axis and demonstrate the utility of mTOR modulators for dissecting tumor biology.

• Baicalin Methyl Ester: Applied Workflows in Intestinal Barri

  2026-04-20

  Baicalin methyl ester stands apart as a precise modulator of the P65/TNF-α/MLCK/ZO-1 pathway, enabling advanced investigation of LPS-induced intestinal barrier damage and anti-inflammatory mechanisms. This article provides actionable protocols, troubleshooting guidance, and comparative insights to streamline research with this esterified derivative of baicalin.

• IPA-3: Optimizing Pak1 Autophosphorylation Inhibition Workfl

  2026-04-20

  Harness the selectivity of IPA-3 for advanced kinase assays and translational studies in cancer and neurobiology. This guide delivers actionable protocols, troubleshooting intelligence, and data-backed recommendations for maximizing reproducibility and insight when deploying this non-ATP-competitive Pak1 inhibitor.

• O-GlcNAcylation Links Wnt Signaling to Aerobic Glycolysis in

  2026-04-19

  This study uncovers how O-GlcNAcylation mediates Wnt-stimulated bone formation by rewiring aerobic glycolysis in osteoblasts. The research clarifies the dual temporal mechanisms underlying Wnt3a-driven metabolic reprogramming, with direct implications for understanding anabolic therapy targets in osteoporosis.

• (Z)-4-Hydroxytamoxifen: Advanced Protocols for ER Modulation

  2026-04-18

  (Z)-4-Hydroxytamoxifen empowers precise modulation of estrogen receptor signaling, outperforming tamoxifen in affinity and antiestrogenic potency. This guide details robust workflows, troubleshooting, and data-driven protocol enhancements for reliable breast cancer modeling and mechanistic studies.

• hiPSC-Derived Sensory Neuron Model for HSV-1 Latency Studies

  2026-04-17

  This study establishes a robust protocol for differentiating human inducible pluripotent stem cells into sensory neurons that support herpes simplex virus 1 (HSV-1) latent infection and reactivation. The scalable in vitro system enables precise dissection of neuron-intrinsic mechanisms underlying HSV-1 latency and reactivation, bridging a key translational gap in herpesvirus research.

• 7ACC2: Precision MCT1 Inhibition for Immunometabolic Cancer

  2026-04-16

  Explore how 7ACC2, a potent monocarboxylate transporter 1 inhibitor, enables advanced study of tumor metabolism and immunoregulatory microenvironments. This article uniquely connects MCT1 inhibition with emerging immunometabolic insights for cancer progression.

• Super-Resolution Mapping of Mitochondrial mRNAs in Apoptotic

  2026-04-15

  This study pioneers the use of STED and MINFLUX super-resolution microscopy combined with single-molecule FISH to visualize and analyze mitochondrial mRNA distribution and organization at nanometer scales. The findings reveal dynamic changes in mitochondrial mRNA architecture during apoptosis, offering new insights into mitochondrial gene regulation and the spatial context of cell death processes.

• Nanoparticle-Delivered PTEN mRNA Reverses Trastuzumab Resist

  2026-04-14

  This article explores a recent study demonstrating how tumor microenvironment-responsive nanoparticles can systemically deliver PTEN mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. The findings highlight a robust approach for restoring tumor suppressor activity and inhibiting the PI3K/Akt pathway, addressing a critical challenge in advanced cancer therapy.

• Anlotinib Hydrochloride: Strategic Leverage for Translationa

  2026-04-13

  This thought-leadership article explores the mechanistic and translational impact of Anlotinib hydrochloride, emphasizing its multi-target inhibition of VEGFR2, PDGFRβ, and FGFR1. By dissecting experimental evidence and clinical insights, it offers actionable guidance for translational researchers seeking to bridge preclinical discovery and clinical innovation in angiogenesis-driven malignancies. Distinct from standard product content, this piece provides protocol parameters, comparative analysis, and a forward-looking outlook—all grounded in rigorous evidence and workflow realities.

• Catalpol Inhibits Liver Fibrosis via EphA2/FAK/Src Pathway M

  2026-04-13

  The referenced study demonstrates that catalpol ameliorates hepatic fibrosis by directly targeting EphA2 and suppressing the FAK/Src signaling pathway, which results in reduced aerobic glycolysis in hepatic stellate cells. These findings highlight a mechanistic link between metabolic reprogramming and fibrogenesis, with implications for future anti-fibrotic drug development.

• Dimethyloxalylglycine (DMOG): Technical Guide for Hypoxia Mo

  2026-04-12

  Dimethyloxalylglycine (DMOG) is a well-established, cell-permeable inhibitor of prolyl-4-hydroxylase domain enzymes, enabling precise stabilization of hypoxia-inducible factor (HIF) for controlled studies of hypoxia signaling and immune regulation. This compound is specifically suited for in vitro and in vivo workflows requiring reproducible HIF-1α stabilization, but is not recommended for diagnostic or therapeutic applications.

• Baicalin Methyl Ester in LPS-Induced Intestinal Barrier Rese

  2026-04-12

  Baicalin methyl ester, a potent esterified derivative of baicalin, enables reproducible modeling and targeted modulation of LPS-induced intestinal barrier damage. Its validated action on the P65/TNF-α/MLCK/ZO-1 pathway delivers both mechanistic clarity and practical workflow flexibility for gut inflammation studies.

• SC 79 Akt Activator: Optimizing Neuroprotection & Cell Survi

  2026-04-11

  SC 79 stands out as a potent, selective Akt activator, transforming neuroprotection workflows and enabling precise manipulation of cell survival pathways. Discover stepwise protocol enhancements, real-world troubleshooting, and how SC 79 advances both ischemic stroke and metabolic research.

• SR 11302: Applied Workflows for AP-1 Transcription Factor In

  2026-04-11

  SR 11302 empowers researchers to selectively inhibit AP-1 signaling with high precision, optimizing cancer cell proliferation assays and in vivo chemoprevention models. Its unique mechanism—blocking AP-1 without retinoid receptor activation—enables advanced study of tumor biology, as demonstrated in recent macrophage polarization research.

16231 records 1/1083 page Next 12345 下5页 Last page